This chapter explores the challenges faced in developing medical diagnostics, emphasizing integrity and regulatory approval. The speakers discuss the Theranos example, addressing skepticism through clinical studies and partnerships. They also highlight the disruption potential of their innovation and the importance of incumbents in the healthcare industry.
The Sunday Times’ tech correspondent Danny Fortson brings on David Stein, chief executive of Babson Diagnostics, to talk about the importance of blood testing (4:49), why Babson is not Theranos (6:47), trying to compete with that idea (9:26), why they succeeded where Theranos failed (14:34), using a tiny amount of blood (18:23), fighting against the Theranos effect (24:37), being owned by a company they aim to disrupt (26:28), liquid biopsies (28:02), the new age of biological data (32:23), regulatory approval (37:09), and avoiding the spotlight (39:03).
Hosted on Acast. See acast.com/privacy for more information.